Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the long-term safety and tolerability of TEV-56286, an oral drug, for adults with Multiple System Atrophy MSA. This Phase 2 trial aims to observe how well participants tolerate the medication over an extended period and to further describe its safety profile. The study is sponsored by Teva Branded Pharmaceutical Products R&D LLC and plans to include participants aged 30 and older. Participants in the trial will receive TEV-56286 orally throughout the study. This open-label extension trial follows up on a previous double-blind trial, focusing on continued treatment and monitoring. The total planned duration for participant involvement is approximately 100 weeks, allowing for long-term observation of safety and tolerability. During the study, participants will undergo regular assessments to monitor adverse events, vital signs, laboratory test results including hematology and chemistry, and 12-lead ECG measurements. Researchers will track any side effects and reasons for withdrawal throughout the 100-week period. The trial includes safety follow-up visits and aims to collect comprehensive data on the long-term effects of TEV-56286 in adults with MSA.